AR032471A1 - Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter - Google Patents
Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos interInfo
- Publication number
- AR032471A1 AR032471A1 ARP010103734A ARP010103734A AR032471A1 AR 032471 A1 AR032471 A1 AR 032471A1 AR P010103734 A ARP010103734 A AR P010103734A AR P010103734 A ARP010103734 A AR P010103734A AR 032471 A1 AR032471 A1 AR 032471A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- processes
- prepare
- preparation
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Abstract
Un derivado de androstano de formula (1) y solvatos del mismo, utiles en el tratamiento de trastornos inflamatorios y/o alérgicos. También se dan a conocer el uso de tales compuestos en la fabricacion de medicamentos, composiciones farmacéuticas que comprenden tales compuestos, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos intermediarios utiles en la preparacion de tales intermediarios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0019172.6A GB0019172D0 (en) | 2000-08-05 | 2000-08-05 | Novel compounds |
GBGB0108800.4A GB0108800D0 (en) | 2001-04-07 | 2001-04-07 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032471A1 true AR032471A1 (es) | 2003-11-12 |
Family
ID=26244792
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103734A AR032471A1 (es) | 2000-08-05 | 2001-08-03 | Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter |
ARP010103733A AR032361A1 (es) | 2000-08-05 | 2001-08-03 | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
ARP080102929A AR063555A1 (es) | 2000-08-05 | 2008-07-07 | Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103733A AR032361A1 (es) | 2000-08-05 | 2001-08-03 | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
ARP080102929A AR063555A1 (es) | 2000-08-05 | 2008-07-07 | Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos |
Country Status (36)
Country | Link |
---|---|
US (3) | US7498321B2 (es) |
EP (5) | EP2348032B1 (es) |
JP (3) | JP2004505990A (es) |
KR (3) | KR100827379B1 (es) |
CN (4) | CN100513416C (es) |
AP (1) | AP1422A (es) |
AR (3) | AR032471A1 (es) |
AT (2) | ATE380194T1 (es) |
AU (4) | AU2001276497B2 (es) |
BG (1) | BG66241B1 (es) |
BR (2) | BRPI0113042B8 (es) |
CA (3) | CA2417825C (es) |
CO (2) | CO5310534A1 (es) |
CY (4) | CY1107899T1 (es) |
CZ (2) | CZ304043B6 (es) |
DE (3) | DE122008000029I1 (es) |
DK (3) | DK1305329T4 (es) |
DZ (1) | DZ3468A1 (es) |
EA (1) | EA005992B1 (es) |
ES (4) | ES2292604T5 (es) |
FR (1) | FR08C0014I2 (es) |
HK (2) | HK1056181A1 (es) |
HU (3) | HU230328B1 (es) |
IL (4) | IL154175A0 (es) |
LU (1) | LU91429I2 (es) |
MA (1) | MA25899A1 (es) |
MX (2) | MXPA03001097A (es) |
NL (1) | NL300343I2 (es) |
NO (4) | NO20030550L (es) |
NZ (2) | NZ523958A (es) |
OA (1) | OA12394A (es) |
PL (2) | PL359917A1 (es) |
PT (3) | PT1775305E (es) |
SI (3) | SI1775305T1 (es) |
SK (1) | SK287576B6 (es) |
WO (2) | WO2002012266A1 (es) |
Families Citing this family (209)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
CO5310534A1 (es) * | 2000-08-05 | 2003-08-29 | Glaxo Group Ltd | Nuevos derivados de androstano anti-inflamatorios |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
CZ20032958A3 (en) | 2001-04-30 | 2004-03-17 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
EP1395604B1 (en) * | 2001-06-12 | 2008-06-25 | Glaxo Group Limited | Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
GB0202216D0 (en) * | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
GB0202564D0 (en) * | 2002-02-04 | 2002-03-20 | Glaxo Group Ltd | Process |
AU2003244451A1 (en) * | 2002-02-04 | 2003-09-02 | Glaxo Group Limited | Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
AU2003205855A1 (en) * | 2002-02-04 | 2003-09-02 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
EP1757281A3 (en) * | 2002-02-04 | 2009-07-15 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
US6928877B2 (en) | 2002-05-24 | 2005-08-16 | Symyx Technologies, Inc. | High throughput microbalance and methods of using same |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
IL153462A0 (en) * | 2002-12-16 | 2003-07-06 | Chemagis Ltd | Thiocarboxylic acid organic salts and processes utilizing the same |
WO2004087731A1 (en) * | 2003-04-04 | 2004-10-14 | Alpharma Aps | Process for the preparation of steroidal carbothioic acid derivatives and intermediates |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
GB0323701D0 (en) * | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
ES2540853T3 (es) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Sales de dicetopiperazina para la administración de fármacos |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
KR20080036632A (ko) | 2005-08-08 | 2008-04-28 | 아젠터 디스커버리 리미티드 | 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도 |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0521563D0 (en) | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
EP1996158A2 (en) * | 2006-03-22 | 2008-12-03 | 3M Innovative Properties Company | Novel formulations |
JP2009530419A (ja) * | 2006-03-22 | 2009-08-27 | グラクソ グループ リミテッド | 新規製剤 |
AU2007242851A1 (en) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Novel compounds |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
ES2296516B1 (es) * | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0612027D0 (en) | 2006-06-16 | 2006-07-26 | Glaxo Group Ltd | Novel process |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
DK2104535T3 (da) | 2007-01-10 | 2011-04-04 | Irm Llc | Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer |
AU2008214214B2 (en) | 2007-02-09 | 2011-09-15 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
PE20091096A1 (es) | 2007-12-10 | 2009-08-25 | Novartis Ag | Compuestos organicos |
EP2245042A1 (en) * | 2007-12-21 | 2010-11-03 | Schering Corporation | C20-c21 substituted glucocorticoid receptor agonists |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
WO2010068311A1 (en) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein inhibitor |
ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
PL2293833T3 (pl) | 2008-06-13 | 2016-08-31 | Mannkind Corp | Inhalator proszkowy i układ do dostarczania leku |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
ES2421385T3 (es) | 2008-06-20 | 2013-09-02 | Mannkind Corp | Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2010016931A2 (en) * | 2008-08-07 | 2010-02-11 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and process for preparation thereof |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8642069B2 (en) * | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PT2379507E (pt) | 2008-12-30 | 2014-01-21 | Pulmagen Therapeutics Inflammation Ltd | Compostos de sulfonamida para o tratamento de desordens respiratórias |
AU2010219097A1 (en) | 2009-01-13 | 2011-08-04 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
ES2739352T3 (es) | 2009-02-26 | 2020-01-30 | Glaxo Group Ltd | Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol |
US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
DK2405963T3 (da) | 2009-03-11 | 2013-12-16 | Mannkind Corp | Apparat, system og fremgangsmåde til at måle modstand i en inhalator |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
WO2010108107A1 (en) * | 2009-03-19 | 2010-09-23 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and processes for preparation thereof |
JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
SG174452A1 (en) | 2009-03-19 | 2011-10-28 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子6(STAT6)遺伝子発現のRNA干渉媒介性阻害 |
JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害 |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2411516A1 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411517A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
CA2758505C (en) | 2009-04-23 | 2017-03-07 | Theravance, Inc. | Diamide compounds having muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activity |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
TW201103892A (en) | 2009-04-24 | 2011-02-01 | Glaxo Group Ltd | Compounds |
ME02053B (me) | 2009-04-30 | 2015-05-20 | Glaxo Group Ltd | Oksazol supstituisani indazoli kao inhibitori pi3-kinaze |
SG175738A1 (en) | 2009-05-29 | 2011-12-29 | Pfizer Ltd | Novel glucocorticoid receptor agonists |
MY157166A (en) | 2009-06-12 | 2016-05-13 | Mankind Corp | Diketopiperazine microparticles with defined specific surface areas |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3−キナーゼ阻害剤としてのインダゾール誘導体 |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
PT105138B (pt) * | 2010-06-01 | 2012-11-06 | Hovione Farmaciencia S A | Método para a preparação de compostos orgânicos monofluorometilados biologicamente activos |
PT105139B (pt) | 2010-06-01 | 2013-01-29 | Hovione Farmaciencia S A | Método para a monofluorometilação de substratos orgânicos para preparação de compostos orgânicos biologicamente activos |
MX359281B (es) | 2010-06-21 | 2018-09-21 | Mannkind Corp | Sistema y metodos para suministrar un farmaco en polvo seco. |
EP2593444B1 (en) | 2010-07-15 | 2015-04-08 | Battelle Memorial Institute | Biobased polyols for potential use as flame retardants in polyurethane and polyester applications |
WO2012025474A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Indazole compounds |
WO2012025473A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
WO2012028662A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2611423B2 (en) | 2010-08-31 | 2022-09-21 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
AU2014200770B2 (en) * | 2010-08-31 | 2015-11-12 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2611821A2 (en) | 2010-09-01 | 2013-07-10 | Cadila Healthcare Limited | Process for preparing fluticasone propionate/furoate |
ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
ES2548036T3 (es) | 2010-09-08 | 2015-10-13 | Glaxosmithkline Intellectual Property Development Limited | Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
US9149462B2 (en) | 2010-10-21 | 2015-10-06 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
CN102558273B (zh) * | 2010-12-14 | 2014-07-02 | 浙江省天台县奥锐特药业有限公司 | 氟替卡松糠酸酯的制备方法 |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
PE20140378A1 (es) | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
SG194034A1 (en) | 2011-04-01 | 2013-11-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
PT105723B (pt) * | 2011-05-26 | 2014-03-24 | Hovione Farmaci Ncia S A | Método para a preparação de compostos orgânicos biologicamente activos |
JP2014518894A (ja) | 2011-06-08 | 2014-08-07 | グラクソ グループ リミテッド | ウメクリジニウムを含む乾燥粉末インヘラー組成物 |
JP2014516062A (ja) | 2011-06-08 | 2014-07-07 | グラクソ グループ リミテッド | ウメクリジニウム及びコルチコステロイドを含む組合せ |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N−置換ヘテロシクリルカルボキサミド類 |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
IN2014DN03093A (es) | 2011-10-24 | 2015-05-15 | Mannkind Corp | |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
JP6267685B2 (ja) | 2012-04-13 | 2018-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 集合粒子 |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
SG10201708090TA (en) | 2013-03-15 | 2017-11-29 | Mannkind Corp | Microcrystalline diketopiperazine compositions and methods |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
WO2014198909A1 (en) | 2013-06-14 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
KR102321339B1 (ko) | 2013-07-18 | 2021-11-02 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
AU2014336251A1 (en) | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
CN106458966B (zh) | 2014-04-24 | 2019-05-07 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
CN106458980A (zh) | 2014-04-24 | 2017-02-22 | 诺华股份有限公司 | 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物 |
KR20170003673A (ko) | 2014-05-12 | 2017-01-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물 |
ES2959699T3 (es) | 2014-05-28 | 2024-02-27 | Glaxosmithkline Ip Dev Ltd | Furoato de fluticasona en el tratamiento de la EPOC |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
TWI679279B (zh) * | 2018-05-09 | 2019-12-11 | 臺中榮民總醫院 | 檢測成人發作型史笛兒氏症之罹病風險及預後之方法 |
CA3100679A1 (en) | 2018-06-08 | 2019-12-12 | Toko Yakuhin Kogyo Co., Ltd. | Fluticasone furoate nasal preparation composition |
AU2019287541A1 (en) | 2018-06-14 | 2021-01-21 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
CN111662353A (zh) * | 2019-03-05 | 2020-09-15 | 上海谷森医药有限公司 | 一种糠酸氟替卡松晶型1的制备方法 |
CA3139634A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
CN114007660A (zh) * | 2019-07-17 | 2022-02-01 | 宝洁公司 | 清新组合物和用热活化的微流体料盒雾化清新组合物的方法 |
CN112823009A (zh) | 2019-08-28 | 2021-05-18 | 上海谷森医药有限公司 | 糠酸氟替卡松脂质体制剂及其制备方法 |
CN114341132A (zh) | 2019-08-28 | 2022-04-12 | 诺华股份有限公司 | 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR580494A (fr) | 1923-07-10 | 1924-11-07 | Const Metalliques Schiltigheim | Procédé d'établissement des buses d'aération ou autres tuyaux |
US2169265A (en) | 1939-05-02 | 1939-08-15 | City Novelty Corp | Linked ornamental chain |
US2837464A (en) * | 1955-01-11 | 1958-06-03 | Schering Corp | Process for production of dienes by corynebacteria |
DE1059906B (de) | 1954-10-05 | 1959-06-25 | Scherico Ltd | Verfahren zur Herstellung von 1, 4-Pregnadienen |
US2816902A (en) † | 1957-01-14 | 1957-12-17 | Schering Corp | Hydroxylated steroids |
US3067197A (en) * | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
GB1158492A (en) | 1966-02-09 | 1969-07-16 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
IT1061787B (it) | 1967-03-01 | 1983-04-30 | Vismara Francesco Spa | Miglioramenti relativi alla preparazione di 17 benzoato di betametazone |
GB1227992A (es) * | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
IT1034011B (it) | 1969-06-26 | 1979-09-10 | Vister Vismara Terapeutici S P | Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato |
GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
BE788444A (fr) * | 1971-09-06 | 1973-01-02 | Sumitomo Chemical Co | Procede de production de 2,5-dimethyl-2,4-hexadiene |
US3828080A (en) * | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
US3808080A (en) * | 1972-06-08 | 1974-04-30 | Bronson Instr Inc | Ultrasonic seaming apparatus |
US3989686A (en) * | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
GB1438940A (en) | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
GB1440063A (en) * | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
DE2336693A1 (de) | 1973-07-19 | 1975-02-06 | Nassheuer Ind Ofenbau Jean | Strahlheizrohr |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1517278A (en) * | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
YU54476A (en) * | 1975-03-31 | 1982-05-31 | Taisho Pharmaceutical Co Ltd | Process for obtaining 17-ester 21-halo-pregnane |
DE2538569A1 (de) | 1975-08-29 | 1977-03-03 | Siemens Ag | Verfahren zur metallisierung von duroplasten |
CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4188385A (en) * | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
US4263289A (en) * | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
US4261984A (en) * | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
US4198403A (en) | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
US4310466A (en) * | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
CY1291A (en) | 1980-02-15 | 1985-10-18 | Glaxo Group Ltd | Androstane 17 beta carbothioates |
CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
ZA814440B (en) | 1980-07-10 | 1982-10-27 | Otsuka Pharma Co Ltd | Soft steroids having anti-inflammatory activity |
US4710495A (en) * | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
DE3260474D1 (en) * | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
CA1224992A (en) | 1982-10-08 | 1987-08-04 | Robert E. Newell | Device for administering medicament to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
EP0179583A1 (en) | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
IL79550A (en) | 1985-07-30 | 1991-06-10 | Glaxo Group Ltd | Devices for administering medicaments to patients |
DE3786174T2 (de) | 1987-10-13 | 1993-10-21 | Nicholas S Bodor | Weiche steroide mit anti-entzündungswirkung. |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
FR2644788B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US5202316A (en) * | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
FR2644787B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
JPH07116215B2 (ja) | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US5250293A (en) * | 1991-04-22 | 1993-10-05 | Gleich Gerald J | Method for the treatment of hypersensitivity diseases by administration of anionic polymers |
TW247878B (es) | 1991-07-02 | 1995-05-21 | Takeda Pharm Industry Co Ltd | |
US6127353A (en) * | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
WO1994021229A1 (en) | 1993-03-17 | 1994-09-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
DE4328819A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
GB9419536D0 (en) * | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
JPH08291072A (ja) | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 吸入用粉末製剤用結晶とその製造方法 |
JPH08291073A (ja) | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
US5707984A (en) * | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
US5792758A (en) | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
NZ324373A (en) * | 1995-12-29 | 1999-10-28 | Glaxo Group Ltd | Lactone derivatives of 17-beta-carboxy, carbonyl-thio and amide androstane derivatives |
US5985862A (en) | 1996-05-02 | 1999-11-16 | G.D. Searle & Co. | Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs |
US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
PT1070056E (pt) | 1998-03-14 | 2004-11-30 | Altana Pharma Ag | Inibidores de pde iii/iv a base de ftalazinona |
US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
GB9828721D0 (en) | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
JP3901945B2 (ja) | 1999-04-30 | 2007-04-04 | ファイザー・プロダクツ・インク | グルココルチコイド受容体モジュレーター |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020081266A1 (en) | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
CO5310534A1 (es) * | 2000-08-05 | 2003-08-29 | Glaxo Group Ltd | Nuevos derivados de androstano anti-inflamatorios |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
DE60134267D1 (de) * | 2000-12-22 | 2008-07-10 | Nippon Shinyaku Co Ltd | Prophylaktische/therapeutische mittel für entzündliche atemwegserkrankungen |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
JP3691459B2 (ja) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
-
2001
- 2001-08-03 CO CO01063014A patent/CO5310534A1/es not_active Application Discontinuation
- 2001-08-03 CN CNB2005100670269A patent/CN100513416C/zh not_active Expired - Lifetime
- 2001-08-03 WO PCT/GB2001/003499 patent/WO2002012266A1/en active IP Right Grant
- 2001-08-03 DE DE122008000029C patent/DE122008000029I1/de active Pending
- 2001-08-03 CO CO01063015A patent/CO5310550A1/es active IP Right Grant
- 2001-08-03 NZ NZ523958A patent/NZ523958A/en unknown
- 2001-08-03 EP EP10179104.4A patent/EP2348032B1/en not_active Expired - Lifetime
- 2001-08-03 JP JP2002518239A patent/JP2004505990A/ja active Pending
- 2001-08-03 KR KR1020037001670A patent/KR100827379B1/ko active IP Right Review Request
- 2001-08-03 JP JP2002518238A patent/JP4436041B2/ja not_active Expired - Lifetime
- 2001-08-03 SI SI200131037T patent/SI1775305T1/sl unknown
- 2001-08-03 NZ NZ523957A patent/NZ523957A/xx not_active IP Right Cessation
- 2001-08-03 CA CA002417825A patent/CA2417825C/en not_active Expired - Lifetime
- 2001-08-03 AU AU2001276497A patent/AU2001276497B2/en not_active Ceased
- 2001-08-03 EP EP01953272.0A patent/EP1305329B2/en not_active Expired - Lifetime
- 2001-08-03 CA CA002417826A patent/CA2417826A1/en not_active Abandoned
- 2001-08-03 AP APAP/P/2003/002731A patent/AP1422A/en active
- 2001-08-03 WO PCT/GB2001/003495 patent/WO2002012265A1/en active Application Filing
- 2001-08-03 SI SI200130796T patent/SI1305329T2/sl unknown
- 2001-08-03 AU AU7576001A patent/AU7576001A/xx active Pending
- 2001-08-03 PL PL01359917A patent/PL359917A1/xx not_active Application Discontinuation
- 2001-08-03 MX MXPA03001097A patent/MXPA03001097A/es not_active Application Discontinuation
- 2001-08-03 SI SI200131046T patent/SI2348032T1/sl unknown
- 2001-08-03 US US10/343,842 patent/US7498321B2/en not_active Expired - Fee Related
- 2001-08-03 AT AT01953272T patent/ATE380194T1/de active
- 2001-08-03 AU AU2001275760A patent/AU2001275760B2/en not_active Expired
- 2001-08-03 DE DE60136818T patent/DE60136818D1/de not_active Revoked
- 2001-08-03 CZ CZ20030352A patent/CZ304043B6/cs not_active IP Right Cessation
- 2001-08-03 HU HU0303354A patent/HU230328B1/hu active Protection Beyond IP Right Term
- 2001-08-03 DE DE60131750.5T patent/DE60131750T3/de not_active Expired - Lifetime
- 2001-08-03 US US09/958,050 patent/US7101866B2/en not_active Expired - Lifetime
- 2001-08-03 BR BRPI0113042-0 patent/BRPI0113042B8/pt not_active IP Right Cessation
- 2001-08-03 DK DK01953272.0T patent/DK1305329T4/da active
- 2001-08-03 OA OA1200300023A patent/OA12394A/en unknown
- 2001-08-03 PT PT71012694T patent/PT1775305E/pt unknown
- 2001-08-03 EP EP01954149A patent/EP1305330B1/en not_active Revoked
- 2001-08-03 MX MXPA03001096A patent/MXPA03001096A/es active IP Right Grant
- 2001-08-03 ES ES01953272.0T patent/ES2292604T5/es not_active Expired - Lifetime
- 2001-08-03 PL PL359999A patent/PL213373B1/pl unknown
- 2001-08-03 DZ DZ013468A patent/DZ3468A1/fr active
- 2001-08-03 PT PT01953272T patent/PT1305329E/pt unknown
- 2001-08-03 HU HU0303084A patent/HUP0303084A2/hu unknown
- 2001-08-03 ES ES07101269.4T patent/ES2523930T3/es not_active Expired - Lifetime
- 2001-08-03 DK DK07101269.4T patent/DK1775305T3/da active
- 2001-08-03 AR ARP010103734A patent/AR032471A1/es active IP Right Grant
- 2001-08-03 AR ARP010103733A patent/AR032361A1/es unknown
- 2001-08-03 SK SK142-2003A patent/SK287576B6/sk not_active IP Right Cessation
- 2001-08-03 CA CA002634715A patent/CA2634715A1/en not_active Abandoned
- 2001-08-03 ES ES01954149T patent/ES2317922T3/es not_active Expired - Lifetime
- 2001-08-03 AT AT01954149T patent/ATE416184T1/de not_active IP Right Cessation
- 2001-08-03 EA EA200300082A patent/EA005992B1/ru not_active IP Right Cessation
- 2001-08-03 PT PT101791044T patent/PT2348032E/pt unknown
- 2001-08-03 AU AU7649701A patent/AU7649701A/xx active Pending
- 2001-08-03 DK DK10179104.4T patent/DK2348032T3/en active
- 2001-08-03 IL IL15417501A patent/IL154175A0/xx unknown
- 2001-08-03 ES ES10179104.4T patent/ES2546830T3/es not_active Expired - Lifetime
- 2001-08-03 CN CNB018166628A patent/CN1294141C/zh not_active Expired - Lifetime
- 2001-08-03 CN CNB018166644A patent/CN1294142C/zh not_active Expired - Fee Related
- 2001-08-03 KR KR10-2003-7001671A patent/KR20030071751A/ko not_active Application Discontinuation
- 2001-08-03 EP EP07101269.4A patent/EP1775305B1/en not_active Expired - Lifetime
- 2001-08-03 CZ CZ2003353A patent/CZ2003353A3/cs unknown
- 2001-08-03 KR KR1020077028068A patent/KR100889426B1/ko active IP Right Grant
- 2001-08-03 EP EP08020059A patent/EP2067784A3/en not_active Withdrawn
- 2001-08-03 BR BR0113039-0A patent/BR0113039A/pt not_active IP Right Cessation
- 2001-08-03 CN CNB2005100530367A patent/CN1315867C/zh not_active Expired - Fee Related
- 2001-08-03 IL IL15414801A patent/IL154148A0/xx unknown
-
2003
- 2003-01-27 IL IL154148A patent/IL154148A/en active IP Right Grant
- 2003-02-04 NO NO20030550A patent/NO20030550L/no unknown
- 2003-02-04 NO NO20030549A patent/NO324747B1/no not_active IP Right Cessation
- 2003-02-04 BG BG107518A patent/BG66241B1/bg unknown
- 2003-02-05 MA MA27028A patent/MA25899A1/fr unknown
- 2003-09-22 HK HK03106798.8A patent/HK1056181A1/zh unknown
- 2003-09-22 HK HK03106795.1A patent/HK1056180B/zh not_active IP Right Cessation
-
2007
- 2007-10-22 NO NO20075376A patent/NO333467B1/no not_active IP Right Cessation
- 2007-12-24 IL IL188364A patent/IL188364A/en active IP Right Grant
-
2008
- 2008-02-29 CY CY20081100241T patent/CY1107899T1/el unknown
- 2008-04-15 NL NL300343C patent/NL300343I2/nl unknown
- 2008-04-16 LU LU91429C patent/LU91429I2/fr unknown
- 2008-04-17 FR FR08C0014C patent/FR08C0014I2/fr active Active
- 2008-04-23 CY CY200800009C patent/CY2008009I2/el unknown
- 2008-05-28 NO NO2008006C patent/NO2008006I2/no not_active IP Right Cessation
- 2008-07-07 AR ARP080102929A patent/AR063555A1/es not_active Application Discontinuation
- 2008-08-28 US US12/199,991 patent/US20080317833A1/en not_active Abandoned
-
2009
- 2009-11-20 JP JP2009265248A patent/JP5150607B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-05 CY CY20141101012T patent/CY1116145T1/el unknown
-
2015
- 2015-09-28 CY CY20151100853T patent/CY1116845T1/el unknown
-
2016
- 2016-03-11 HU HUS1600012C patent/HUS1600012I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR032471A1 (es) | Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter | |
AR045900A1 (es) | Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos. | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
AR003220A1 (es) | Derivados acilados de melatonina; composicion farmaceutica y cosmetica y el uso de los mismos para la preparacion de un medicamento. | |
UY28339A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
MX9305769A (es) | Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR029175A1 (es) | Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento | |
BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
BRPI0507877A (pt) | derivados de formamida, composição farmacêutica, uso dos mesmos e combinação | |
SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
AR007827A1 (es) | 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos. | |
CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
AR012294A1 (es) | Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento. | |
CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
UY28317A1 (es) | Compuestos útiles para el tratamiento de enfermedades | |
ES2178055T3 (es) | Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
MX9300628A (es) | Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
BRPI0410623A (pt) | composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto | |
CL2004000779A1 (es) | Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |